ClassID:

21148

A61K39/39533 - page 3 - CPC Classification

Classification description:

Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals

Recent Application in this class:
#601
20110287006
2011-11-24

COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT

#602
20110286990
2011-11-24

Methods of diagnosing and treating fibrosis

#603
20110256215
2011-10-20

NON-PEGYLATED LIPOSOMAL DOXORUBICIN TRIPLE COMBINATION THERAPY

#604
20110243927
2011-10-06

METHODS OF INHIBITING TUMOR GROWTH USING BETA 5 INTEGRIN ANTAGONISTS

#605
20110189082
2011-08-04

Human GM-CSF antigen binding proteins

#606
20110154306
2011-06-23

Methods and apparatuses for endian conversion

#607
20110150902
2011-06-23

TREATING CANCER

#608
20110142851
2011-06-16

Antagonists of IL-6

#609
20110142832
2011-06-16

Soluble tumor necrosis factor receptor treatment of medical disorders

#610
20110129456
2011-06-02

Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer

#611
20110118181
2011-05-19

PCSK9 inhibitors and methods of use thereof

#612
20110086025
2011-04-14

Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent

#613
20110038831
2011-02-17

Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators

#614
20110033454
2011-02-10

Methods For Treating Diseases Using Antibodies to Aminophospolipids

#615
20110008352
2011-01-13

Toll-like receptor 3 antagonists

#616
20100323004
2010-12-23

Non-pegylated liposomal doxorubicin triple combination therapy

#617
20100322942
2010-12-23

THERAPEUTIC AND PROPHYLACTIC METHODS FOR NEUROMUSCULAR DISORDERS

#618
20100316593
2010-12-16

Pharmaceutical formulations

#619
20100291081
2010-11-18

Rage fusion proteins

#620
20100285106
2010-11-11

MULTICOMPONENT VACCINE

#621
20100285021
2010-11-11

Antibodies which bind factor VIII

#622
20100260831
2010-10-14

NON-PEGYLATED LIPOSOMAL DOXORUBICIN TRIPLE COMBINATION THERAPY

#623
20100260748
2010-10-14

Anti-FcRH5 antibodies and immunoconjugates and methods of use

#624
20100233121
2010-09-16

METHOD FOR TREATING MULTIPLE SCLEROSIS

#625
20100215671
2010-08-26

Combination therapy with antibody-drug conjugates

#626
20100196392
2010-08-05

Anti-system ASC amino acid transporter 2 (ASCT2) antibody

#627
20100196385
2010-08-05

Targeted antibodies directed to DLL4

#628
20100172905
2010-07-08

HMG1 antibody for treating inflammatory conditions

#629
20100172895
2010-07-08

Human CGRP receptor binding proteins

#630
20100166778
2010-07-01

Toll-like receptor 3 antagonists

#631
20100166745
2010-07-01

Transferrin receptor antibodies

#632
20100150905
2010-06-17

KIM-1 antibodies for treatment of TH2-mediated conditions

#633
20100143362
2010-06-10

LINGO binding molecules and pharmaceutical use thereof

#634
20100136029
2010-06-03

Use of Tri-Substituted Glycerol Compounds for the Treatment of Hematological Malignancies

#635
20100136019
2010-06-03

Method of inhibiting regulatory T-cell activity by administering an antibody that inhibits interleukin 35

#636
20100135901
2010-06-03

COMBINATION THERAPY

#637
20100129357
2010-05-27

Antibodies to IL-6 and use thereof

#638
20100125127
2010-05-20

BSL2v1c2 polypeptides

#639
20100104575
2010-04-29

Methods of impairing osteoclast differentiation using antibodies that bind siglec-15

#640
20100086996
2010-04-08

Genetically modified human natural killer cell lines

#641
20100086486
2010-04-08

Genetically modified human natural killer cell lines

#642
20100076178
2010-03-25

Dual variable domain immunoglobulins and uses thereof

#643
20100040537
2010-02-18

Prostaglandin E2 binding proteins and uses thereof

#644
20100028339
2010-02-04

COMPOSITIONS INCLUDING TRICIRIBINE AND TRASTUZUMAB AND METHODS OF USE THEREOF

#645
20090324542
2009-12-31

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS

#646
20090304687
2009-12-10

METHODS OF USING CD40 BINDING AGENTS

#647
20090298763
2009-12-03

Polynucleotides and polypeptide sequences involved in the process of bone remodeling

#648
20090263916
2009-10-22

Antagonists of HMG1 for treating inflammatory conditions

#649
20090232829
2009-09-17

Methods and compositions for treating inflammatory conditions

#650
20090191182
2009-07-30

Compositions, kits, and methods for the modulation of immune responses using galectin-1

#651
20090175849
2009-07-09

NOTCH inhibition in the treatment of atherosclerosis

#652
20090163424
2009-06-25

Soluble tumor necrosis factor receptor treatment of medical disorders

#653
20090155176
2009-06-18

Compositions and methods for treatment of diabetic retinopathy

#654
20090117131
2009-05-07

Pharmaceutical Composition for The Treatment or Prevention of Allergic Diseases, Use Thereof, and A Method for The Treatment or Prevention of Allergic Diseases

#655
20090110679
2009-04-30

Methods and compositions for pulmonary administration of a TNFa inhibitor

#656
20090098118
2009-04-16

COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT

#657
20090074757
2009-03-19

Antitumor Combination Comprising Substituted Acryloyl Distamycin Derivatives and Antibodies Inhibiting Growth Factors or Their Receptors

#658
20090047285
2009-02-19

Antibodies that bind the glutamate ligand binding region of Notch1

#659
20090004109
2009-01-01

Antibodies and molecules derived therefrom that bind to STEAP-1 proteins

#660
20080317741
2008-12-25

Biomarkers For Anti-Nogo-A Antibody Treatment in Spinal Cord Injury

#661
20080311118
2008-12-18

Vascular endothelial cell growth factor antagonists and uses thereof

#662
20080299132
2008-12-04

Synergistic compositions for treating HIV-1

#663
20080299116
2008-12-04

Vascular endothelial cell growth factor antagonists and uses thereof

#664
20080247990
2008-10-09

GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES

#665
20080206192
2008-08-28

Combination Therapy

#666
20080118505
2008-05-22

Reagents and treatment methods for autoimmune diseases

#667
20080081041
2008-04-03

Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer

#668
20070286855
2007-12-13

IMPROVING TREATMENTS

#669
20070265203
2007-11-15

Methods and compositions for modulation of blood-neural barrier

#670
20070264260
2007-11-15

Treatment methods using anti-CD22 antibodies

#671
20070258980
2007-11-08

Vascular endothelial cell growth factor antagonists and uses thereof

#672
20070202503
2007-08-30

Pharmaceutical Composition Of (+)-Erythro-Mefloquine And Its Use

#673
20070122414
2007-05-31

Surface marker-directed cancer therapeutics

#674
20070086999
2007-04-19

Compositions and methods including a recombinant human MAB that promotes CNS remyelination

#675
20070053871
2007-03-08

Pharmaceutical formulations

#676
20070031374
2007-02-08

Combination therapy

#677
20060292156
2006-12-28

Genetically modified human natural killer cell lines

#678
20060240019
2006-10-26

Antagonists of HMG1 for treating inflammatory conditions

#679
20060210565
2006-09-21

Methods of diagnosing sepsis by measuring HMG1

#680
20060205809
2006-09-14

Pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease

#681
20060165710
2006-07-27

Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes

#682
20060159685
2006-07-20

Polynucleotides encoding BSL2v1c2-Ig

#683
20060127403
2006-06-15

Use of antibodies against tumor-associated antigen

#684
20060115474
2006-06-01

Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII

#685
20060051345
2006-03-09

Method for treating multiple sclerosis

#686
20060046979
2006-03-02

Organic compounds

#687
20060039908
2006-02-23

Transferrin receptor antibodies

#688
20060036086
2006-02-16

Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases

#689
20060018904
2006-01-26

Combination therapies utilizing benzamide inhibitors of the P2X7 receptor

#690
20050255112
2005-11-17

Compositions and methods for preventing erythropoietin-associated hypertension

#691
20050249663
2005-11-10

Coadministration of transport protein with conjugated cobalamin to deliver agents

#692
20050244405
2005-11-03

Vascular endothelial cell growth factor antagonists and uses thereof

#693
20050123540
2005-06-09

Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications

#694
20050053611
2005-03-10

Pharmaceutical kit comprising anti-human seminal plasma protein single chain antibody/human carboxypeptidase fusion protein and prodrug

#695
20050053599
2005-03-10

Vascular endothelial cell growth factor antagonists and uses thereof

#696
20050014733
2005-01-20

Therapeutic methods for muscular or neuromuscular disorders

#697
16784052
2026-06-02

Autoinjector comprising high concentration formulation of vedolizumab